Medical Advocates
Nevirapine (Viramune)
 
Journal Citations: Adverse Events

General Reports
Cardiovascular Disorders
Cutaneous Disorders
 Hepatic Disorders
 Renal Disorders
 Hypersensitivity
Mental Disorders
 Meningoencephalitis
 Oral Disorders
 Stevens-Johnson Syndrome/Toxic Epidermal Necrosis 

 
NVP Main Page Journal Main Page New/Newsworthy Home Page
Last Update:  January 03, 2009
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       
 
Nevirapine Toxicity in Non-HIV Cancer Patients.
 Landriscina M, Fabiano A, Lombardi V, et al 
Chemotherapy. 2008 Oct 2;54(6):475-478.
 Abstract
 
Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens :
CD4+ T-Cell Count and Gender in Hepatitis C Seropositive and Seronegative Patients.
 Torti C, Costarelli S, De Silv
 Abstract
 
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant
women.
Phanuphak N, Apornpong T, Teeratakulpisarn S, et al
HIV Med. 2007 Sep;8(6):357-66.
 Abstract
 
Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4
count.
Tansuphaswadikul S, Aung SE, Phonrat B, et al
Asian Pac J Allergy Immunol. 2007 Jun-Sep;25(2-3):147-54.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Nevirapine toxicity.
 Taiwo BO.
 Int J STD AIDS. 2006 Jun;17(6):364-70.
 Abstract
Cardiovascular Disorders
       
  FULL-TEXT ARTICLE
 Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-
Therapy-Naive Patients Infected with HIV-1
van Leth F, Phanuphak P, Stroes E, et al
PLOS Vol2 Issue 9 Sep 2005
 Paper
Cutaneous
       
 
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
 Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al  
Pharmacogenet Genomics. 2009 Dec 19
 Abstract
 
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
 Vitezica ZG, Milpied B, Lonjou C, et al 
AIDS. 2008 Feb 19;22(4):540-1.
Abstract
 
Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients
with CD4 cell counts <250 cells/muL.
 Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, et al 
Int J STD AIDS. 2007 Nov;18(11):782-786.
 Abstract
 
Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
 Daniel OJ, Krain AB, Ogun SA, Odusoga OL, Boyle BA.  
J Natl Med Assoc. 2005 Dec;97(12):1719-21.
 Abstract
 
Case reports: treatment of nevirapine-associated dress syndrome with intravenous
immune globulin (IVIG).
 Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P.
J Drugs Dermatol. 2005 Jul-Aug;4(4):510-3
 Abstract
 
Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz.
Hartmann M, Brust J, Schuster D, et al 
Hautarzt. 2005 Feb 23
 Abstract
 
Incidence and risk factors for rash in Thai patients randomized to regimens with
nevirapine, efavirenz or both drugs.
 Ananworanich J, Moor Z, Siangphoe U, et a;
AIDS. 2005 Jan 28;19(2):185-192
 Abstract
 
Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully
with a combination of intravenous immunoglobulins and N-acetylcysteine.
 Claes P, Wintzen M, Allard S, 
Eur J Intern Med. 2004 Jul;15(4):255-258.
Abstract
 
Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to
nevirapine therapy:results of the viramune-zyrtec double-blind, placebo-controlled trial.
 Launay O, Roudiere L, Boukli N, et al   
Clin Infect Dis. 2004 Apr 15;38(8):e66-7|
 Abstract
 
Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by
Non-HIV-Infected Individuals.
 Patel SM, Johnson S, Belknap SM, et al 
J Acquir Immune Defic Syndr. 2004 Feb 1; 35(2): 120-125
 Abstract
 
Incidence and risk factors for nevirapine-associated rash.
De Maat MM, Ter Heine R, Mulder JW, et al.
Eur J Clin Pharmacol. 2003 Aug 12
 Abstract

Failure of a Short-Term Prednisone Regimen to Prevent Nevirapine-Associated Rash:
A Double-Blind Placebo-Controlled Trial: The GESIDA 09/99 Study.
Knobel H, Miro JM, Domingo P, et al. 
J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):14-18.
 Abstract

Female sex and the use of anti-allergic agents increase the risk of developing
cutaneous rash associated with nevirapine therapy.
Antinori A, Baldini F, Girardi E, et al
AIDS 2001 Aug 17;15(12):1579-81
Abstract
 
Hepatic Disorders
           
 
Hepatotoxicity in patients prescribed efavirenz or nevirapine.
 Brück S, Witte S, Brust J, et al
Eur J Med Res. 2008 Jul 28;13(7):343-8.
 Abstract
 
Risk for immune-mediated liver reactions by nevirapine revisited.
Medrano J, Barreiro P, Tuma P, et al
AIDS Rev. 2008 Apr-Jun;10(2):110-5.
 Abstract
 
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and
CD4 cell counts.
 De Lazzari E, León A, Arnaiz JA, et al 
HIV Med. 2008 Apr;9(4):221-6.
 Abstract
 
Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients
with CD4 cell counts less than 250 cells/microL.
 Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, et al
J Med Assoc Thai. 2008 Feb;91(2):159-65.
 Abstract
 
Liver transplantation for fulminant hepatitis related to nevirapine therapy.
 Buyse S, Vibert E, Sebagh M, et al
Liver Transpl. 2006 Nov 28;12(12):1880-1882
Abstract
 
Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a
baseline CD4 cell count greater than 250 cells/mul
 Manfredi R, Calza L.  
AIDS. 2006 Nov 14;20(17):2233-2236.
Abstract
 
Hepatic failure due to nevirapine treatment for HIV infection.
 Katzenstein TL.  
Ugeskr Laeger. 2005 Nov 14;167(46):4359.
 Abstract
 
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
 Sanne I, Mommeja-Marin H, Hinkle J, et al   
J Infect Dis. 2005 Mar 15;191(6):825-9.
 Abstract
 
Severe Leukopenia Associated with Mild Hepatotoxicity in an HIV Carrier Treated
with Nevirapine.
 Shahar E, Krivoy N, Weltfriend S, Pollack S.
Jpn J Infect Dis. 2004 Oct;57(5):212-3.
 Abstract
 
The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver
Function Tests.
Almond LM, Boffito M, Hoggard PG, et al  
AIDS Res Hum Retroviruses. 2004 Jul;20(7):716-22.
Abstract
 
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic
hepatitis C: harmful impact of nevirapine.
 Macias J, Castellano V, Merchante N, et al.   
AIDS. 2004 Apr 12;18(5):767-774.
 Abstract
 
Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by
Non-HIV-Infected Individuals.
 Patel SM, Johnson S, Belknap SM, et al 
J Acquir Immune Defic Syndr. 2004 Feb 1; 35(2): 120-125
 Abstract
 
Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and
efavirenz-containing regimens in HIV-infected patients.
 Ena J, Amador C, Benito C, Fenoll V. et al 
Int J STD AIDS. 2003 Nov;14(11):776-81.
Abstract  
 
Case series of acute hepatitis in a non-selected group of HIV-infected patients on
nevirapine-containing antiretroviral treatment.
 De Maat MM, Ter Heine R, Van Gorp EC, et al
AIDS. 2003 Oct 17;17(15):2209-14
 Abstract  

Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine.
Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V
 HIV Clin Trials 2003 Mar-Apr;4(2):115-120
Abstract

Hepatotoxicity Following Nevirapine-Containing Regimens in HIV-1-Infected Individuals.
 De Maat M, Mathot R, Veldkamp A, et al.
Pharmacol Res 2002 Sep;46(3):295
 Abstract

FULL-TEXT ARTICLE
 Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: 
a case report.
 Gokengin D, Yamazhan T.
Ann Clin Microbiol Antimicrob 2002 Sep 16;1(1):1
 Paper

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy:  
Role of hepatitis C and B infections.
Sulkowski MS, Thomas DL, Mehta SH, et al.
Hepatology 2002 Jan;35(1):182-9
 Abstract 

Nevirapine-induced hepatitis: a case series and review of the literature.
 Piliero PJ, Purdy B.
AIDS Read 2001 Jul;11(7):379-82
 Abstract

Late onset hepatitis and prolonged deterioration in hepatic function associated with
Nevirapine therapy.
 Clarke S., Harrington P., Condon C., et al
 Int Journal STD AIDS 2000:11:336-337
Abstract
 
 
Renal Disorders
   
 
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
Mauss S; Berger F; Schmutz, Guenther , et al  
 AIDS. 19(1):93-95, January 3, 2005.
 Abstract
 
 
Hypersensitivity
   
 
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
 Vitezica ZG, Milpied B, Lonjou C, et al 
AIDS. 2008 Feb 19;22(4):540-1.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis
C status and mortality in antiretroviral drug-naive HIV-positive patients.
 Phillips E, Gutiérrez S, Jahnke N, et al 
AIDS. 2007 Jul 31;21(12):1561-156
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench
and back again.
 Martin A, Nolan D, Almeida CA, Rauch A, Mallal S. 
Pharmacogenomics. 2006 Jan;7(1):15-23.
Abstract
 
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and
abrogated by low CD4 T-cell counts.
Martin, AM,  Nolan, D, James I, et al    
AIDS. 19(1):97-99, January 3, 2005.
 Abstract

Hypersensitivity syndrome (DRESS) and meningoencephalitis  associated with
nevirapine therapy.
Lanzafame M, Rovere P, et al.
Scand J Infect Dis 2001;33(6):475-6
Abstract

  
Mental Disorders
 		    
  FULL-TEXT ARTICLE
 Neuropsychiatric complications of nevirapine treatment. 
 Wise MEJ K Mistry, S Reid. 
 BMJ 2002;324:879 ( 13 April )
 Paper
Meningoencephalitis
           
  Hypersensitivity syndrome (DRESS) and meningoencephalitis  associated with
nevirapine therapy.
Lanzafame M, Rovere P, et al.
Scand J Infect Dis 2001;33(6):475-6
Abstract		  
Oral Disorders
           
  Oral adverse effects due to the use of Nevirapine.
 Moura MD, Senna MI, Madureira DF, et al
J Contemp Dent Pract. 2008 Jan 1;9(1):84-90.
Abstract		  
Stevens-Johnson Syndrome/Toxic Epidermal Necrosis
           
 
Fatal outcome of nevirapine-associated toxic epidermal necrolysis.
 Leng K, Lonsdorf A, Hartmann M.
Int J STD AIDS. 2008 Sep;19(9):642-3.
 Abstract
 
Nevirapine-induced Stevens-Johnson Syndrome in an HIV Patient.
 Jain V, Shome D, Natarajan S.  |
Cornea. 2008 Apr;27(3):366-367.
 Abstract

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, , et al. 
AIDS 2001 Sep 28;15(14):1843-1848
 Abstract
 

NVP Main Page Journal Main Page New/Newsworthy Home Page

Nevirapine Journal Data
Adverse Events